当前位置: X-MOL 学术J. Natl. Cancer Inst. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Editorial: Circulating Biomarkers to Identify Patients With Resectable Pancreatic Cancer
Journal of the National Cancer Institute ( IF 10.3 ) Pub Date : 2017-02-27 , DOI: 10.1093/jnci/djx004
Michael Goggins 1
Affiliation  

In this issue of the Journal, Killary et al. evaluate a plasma biomarker combination (CA19-9, tissue factor pathway inhibitor [TFPI], and an isoform of tenascin C [TNC-FNIII-B]) for its ability to distinguish patients with early-stage pancreatic cancer from controls (1). The authors previously reported their initial experience evaluating these biomarkers (2). The authors’ study design had several strengths, including the use of multiple disease control groups, blinded analysis of samples, and multiple rounds of validation. The authors found their biomarker panel worked best when compared with controls without pancreatitis or diabetes, finding it could distinguish patients with low-stage pancreatic cancer from healthy controls with an accuracy of 82% (compared with 69% for CA19-9 alone, corresponding to 81% sensitivity, 84% specificity).

中文翻译:

社论:循环生物标志物,以鉴定可切除的胰腺癌患者

在本期杂志中,Killary等人。评估血浆生物标志物组合(CA19-9,组织因子途径抑制剂[TFPI]和腱糖蛋白C的同工型[TNC-FNIII-B])具有区分早期胰腺癌患者和对照组的能力(1)。作者先前报告了他们对这些生物标记物进行评估的初步经验(2)。作者的研究设计具有多种优势,包括使用多个疾病对照组,对样品进行盲法分析以及多轮验证。作者发现,与没有胰腺炎或糖尿病的对照组相比,他们的生物标志物组最有效,发现它可以将低级胰腺癌患者与健康对照组区分开来,准确度为82%(而CA19-9仅为69%,对应于81%的敏感性,84%的特异性)。
更新日期:2017-02-27
down
wechat
bug